Celgene (CELG) PT Set at $128.00 by Credit Suisse Group
Celgene (NASDAQ:CELG) has been given a $128.00 price target by stock analysts at Credit Suisse Group in a research report issued on Tuesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective points to a potential upside of 18.30% from the stock’s previous close.
Several other research analysts also recently issued reports on the stock. BMO Capital Markets upped their price target on shares of Celgene from $148.00 to $155.00 and gave the stock an “outperform” rating in a report on Friday, November 17th. Oppenheimer reiterated a “buy” rating and set a $170.00 price target on shares of Celgene in a report on Friday, October 20th. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price target for the company in a report on Monday, October 23rd. Cann reiterated a “buy” rating on shares of Celgene in a report on Thursday, October 26th. Finally, Morgan Stanley upgraded shares of Celgene from an “underweight” rating to an “equal weight” rating in a report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the stock. Celgene has an average rating of “Buy” and a consensus target price of $136.21.
Celgene (NASDAQ:CELG) opened at $108.20 on Tuesday. Celgene has a 1 year low of $94.55 and a 1 year high of $147.17. The company has a market cap of $85,190.00, a P/E ratio of 16.88, a price-to-earnings-growth ratio of 0.83 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65.
In related news, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the sale, the insider now owns 3,925 shares of the company’s stock, valued at $564,768.25. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.95% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Thompson Davis & CO. Inc. boosted its position in Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 43 shares during the last quarter. Arcadia Investment Management Corp MI boosted its position in Celgene by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 400 shares during the last quarter. Robecosam AG bought a new stake in Celgene during the third quarter valued at $114,000. Guidant Wealth Advisors bought a new stake in Celgene during the third quarter valued at $119,000. Finally, Capital Bank & Trust Co boosted its position in Celgene by 166.8% during the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 517 shares during the last quarter. 80.16% of the stock is currently owned by institutional investors.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Stock Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related stocks with our FREE daily email newsletter.